Pharmaceutical composition containing mirabegron
US-2015031734-A1 · Jan 29, 2015 · US
Pharmaceutical composition containing mirabegron
US10058536B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10058536-B2 |
| Application number | US-201615553107-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2016 |
| Priority date | Mar 31, 2015 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate. 2. The pharmaceutical composition according to claim 1 , wherein the content of the hydrophobic substance is 0.5% by weight to 35% by weight with respect to the weight of the thickener. 3. The pharmaceutical composition according to claim 1 or 2 , wherein the thickener is one member or two or more members selected from the group consisting of xanthan gum, guar gum, locust bean gum, gellan gum, carboxymethyl cellulose sodium, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, carrageenan, methylcellulose, sodium alginate, hypromellose, and polyvinyl alcohol. 4. The pharmaceutical composition according to claims 1 or 2 wherein the thickener is xanthan gum. 5. The pharmaceutical composition according to claim 1 or 2 , wherein the content of the thickener is 1% by weight to 70% by weight with respect to the weight of the pharmaceutical composition. 6. The pharmaceutical composition according to claim 1 or 2 , wherein the pharmaceutical composition is a ready-to-suspend pharmaceutical composition. 7. The pharmaceutical composition according to claim 1 or 2 , wherein the pharmaceutical composition is a pharmaceutical composition for oral administration. 8. The pharmaceutical composition according to claim 1 or 2 , wherein the pharmaceutical composition is a pharmaceutical composition for treating one member or two or more members selected from the group consisting of urinary urgency, urinary frequency, urge urinary incontinence, and neuropathic detrusor overactivity, which are associated with overactive bladder. 9. A method for modifying the release of mirabegron, the method comprising: administering a composition comprising a complex with mirabegron or a pharmaceutically acceptable salt thereof and sodium polystyrene, a thickener and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
of the bladder · CPC title
Drugs for disorders of the urinary system · CPC title
Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title
Dispersions; Emulsions · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10058536B2 cover?
- To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or…
- Who is the assignee on this patent?
- Astellas Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/426. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).